Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients

Table 1 Patient and tumor characteristics

Variable	Interval ≤ 9 wk (group A, n = 139)	Interval > 9 wk (group B, n = 92)	P value
Sex, n (%)			0.279
Male	100 (71.9)	60 (65.2)
Female	39 (28.1)	32 (34.8)
Age (year, mean ± SD)	58.6 ± 10.6	58.9 ± 11.7	0.645
ASA, n (%)			0.280
1	4 (2.9)	3 (3.3)
2	111 (79.9)	67 (72.8)
3	24 (17.2)	22 (23.9)
BMI (kg/m2 , mean ± SD)	23.8 ± 3.4	24.4 ± 2.9	0.063
cT, n (%)			0.318
2	2 (1.4)	0 (0)
3	110 (79.1)	70 (76)
4	27 (19.4)	22 (24)
cN, n (%)			0.355
0	40 (28.8)	22 (23.9)
1	71 (51.1)	48 (52.2)
2	28 (20.1)	22 (23.9)
Preoperative carcinoembryonic antigen (μg/L, mean ± SD)	5.4 ± 10.8	5.8 ± 13.7	0.182
Preoperative concurrent chemotherapy regimen, n (%)			0.712
Capecitabine + oxaliplatin	32 (23)	29 (31.5)
Capecitabine oral	87 (62.6)	58 (63)
Oxaliplatin union	21 (15.1)	5 (5.4)

BMI: Body mass index; ASA: American Society of Anesthesiologists.